JP2024511137A5 - - Google Patents

Info

Publication number
JP2024511137A5
JP2024511137A5 JP2023558578A JP2023558578A JP2024511137A5 JP 2024511137 A5 JP2024511137 A5 JP 2024511137A5 JP 2023558578 A JP2023558578 A JP 2023558578A JP 2023558578 A JP2023558578 A JP 2023558578A JP 2024511137 A5 JP2024511137 A5 JP 2024511137A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdrl1
cdrl2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/057555 external-priority patent/WO2022200389A1/en
Publication of JP2024511137A publication Critical patent/JP2024511137A/ja
Publication of JP2024511137A5 publication Critical patent/JP2024511137A5/ja
Pending legal-status Critical Current

Links

JP2023558578A 2021-03-22 2022-03-22 Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法 Pending JP2024511137A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163164329P 2021-03-22 2021-03-22
US63/164,329 2021-03-22
US202263317899P 2022-03-08 2022-03-08
US63/317,899 2022-03-08
PCT/EP2022/057555 WO2022200389A1 (en) 2021-03-22 2022-03-22 Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024511137A JP2024511137A (ja) 2024-03-12
JP2024511137A5 true JP2024511137A5 (cg-RX-API-DMAC7.html) 2025-03-31

Family

ID=81384718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558578A Pending JP2024511137A (ja) 2021-03-22 2022-03-22 Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法

Country Status (7)

Country Link
US (1) US12448444B2 (cg-RX-API-DMAC7.html)
EP (1) EP4314065A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511137A (cg-RX-API-DMAC7.html)
AU (1) AU2022245196A1 (cg-RX-API-DMAC7.html)
CA (1) CA3212056A1 (cg-RX-API-DMAC7.html)
IL (1) IL305827A (cg-RX-API-DMAC7.html)
WO (1) WO2022200389A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512574A (ja) * 2021-03-22 2024-03-19 ノビミューン エスアー Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
EP4580755A1 (en) * 2022-09-02 2025-07-09 Novimmune S.A. Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof
AU2023362569A1 (en) * 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1
IL328540A (en) * 2023-12-22 2026-07-01 Numab Therapeutics AG Antibody binding complexes specific for LILRB2

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトIgG4抗体
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
EP2513312B1 (en) 2009-12-17 2015-03-18 NovImmune SA Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
WO2019016411A1 (en) 2017-07-21 2019-01-24 Novimmune Sa GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE
CA3084626A1 (en) * 2017-12-04 2019-06-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
CN112566938B (zh) 2018-06-03 2025-04-01 拉姆卡普生物测试有限公司 针对ceacam5和cd47的双特异性抗体
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
JP2024512574A (ja) 2021-03-22 2024-03-19 ノビミューン エスアー Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法

Similar Documents

Publication Publication Date Title
JP2024512574A5 (cg-RX-API-DMAC7.html)
JP2020526478A5 (cg-RX-API-DMAC7.html)
TWI487712B (zh) 多重特異性抗體
CN101939336B (zh) Axl抗体
JP2022101693A5 (cg-RX-API-DMAC7.html)
ES2577292T3 (es) Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2025092589A5 (cg-RX-API-DMAC7.html)
US9994632B2 (en) Humanized or affinity-matured anti Ang-2 antibody and uses thereof
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2019509737A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2018503365A5 (cg-RX-API-DMAC7.html)
JP2022509156A5 (cg-RX-API-DMAC7.html)
JP2016510002A5 (cg-RX-API-DMAC7.html)
JP2012532851A5 (cg-RX-API-DMAC7.html)
JP2023133432A5 (cg-RX-API-DMAC7.html)
JP2024102055A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2025507817A5 (cg-RX-API-DMAC7.html)
JP2023509215A5 (cg-RX-API-DMAC7.html)
JP2025000617A (ja) T細胞受容体のデルタ1鎖に特異的な抗体
JP2023549316A5 (cg-RX-API-DMAC7.html)
JP2024020436A5 (cg-RX-API-DMAC7.html)
JP2025513745A5 (cg-RX-API-DMAC7.html)